









This article has been accepted for publication and undergone full peer review but has not been 
through the copyediting, typesetting, pagination and proofreading process, which may lead to 
differences between this version and the Version of Record. Please cite this article as doi: 
10.1002/acr.40373 
This article is protected by copyright. All rights reserved. 




Bench to Bedside – and Back Again: Finding the Goldilocks Zone within the Scleroderma 
Universe 
Janet E. Pope, MD, MPH, FRCPC 1, Jason J Lee, MD, FRCPC,2 and Dr. Christopher P. Denton,3 
PhD FRCP 
 
1 Division Head Rheumatology, St. Joseph’s Health Care, Professor of Medicine, Dept of Medicine, 
UWO 
2 PhD candidate, University of Western Ontario, Faculty of Medicine 
3 Royal Free Hospital and UCL Medical School, Centre of rRheumatology 
Christopher P Denton BSc, MB, BS, MRCP (UK), PhD, CCST, FRCP 
Corresponding author: Janet Pope, Professor of Medicine, Division of Rheumatology, St. 
Joseph’s Health Care, 268 Grosvenor St. London ON N6A 4V2, janet.pope@sjhc.london.on.ca, 
519-646-6332 phone and 519-646-6334 fax.  
 JEP, CD, JL:  Nothing to disclose, no conflicts of interest. There was no funding for this 
editorial.  
 












This article is protected by copyright. All rights reserved. 
 Systemic sclerosis (SSc) is a complex inflammatory connective tissue disease 
characterized by skin thickening, organ fibrosis and vasculopathy [1, 2]. The underlying disease 
mechanisms and pathophysiology are not fully understood. However, it appears to be, at least 
in part, driven by autoimmunity and inflammation associated with microvascular dysfunction 
ultimately resulting in excess extracellular matrix deposition in target organs [2-4]. Clinical 
heterogeneity coupled with our lack of understanding of the disease pathogenesis means that 
current treatment strategies are mostly organ based therapies using anti-rheumatic drugs that 
were originally approved for other indications [5]. Of course, this clinical diversity not only 
provides challenges to discovery of disease mechanisms, it also complicates often 
underpowered clinical trials that aim to find the right drugs for the right patient at the right 
time. 
 One approach towards discovery of the “Goldilocks Zone” of disease modifying therapy 
for all patients with SSc is starting at a point of known commonality. For example, SSc is often 
characterized by the presence of autoantibodies [6, 7]. More specifically, there have been 
recent interest in B-cell biology and modulation, including data derived from animal models of 
disease, human tissue analyses and even small randomized clinical trials of B-cell depletion in 
patients with SSc [6, 8, 9]. In addition to their role in autoantibody formation, B-cells have been 
shown to be elevated in blood and tissue samples of patients with SSc, with abnormal chronic 
activation while demonstrating secretion of important disease cytokines such as IL-6 and TGF-β 
[6].  
In this issue of Arthritis and Rheumatology, Gordon et al present their experience with 
belimumab in a randomized placebo controlled trial. Belimumab is a human monoclonal 
antibody directed against B-cell Activating Factor (BAFF), also known as B-lymphocyte 
Stimulator (BLyS). This study assessed the potential benefit of adding belimumab to standard 
treatment of early diffuse cutaneous SSc (dcSSc) with mycophenolate mofetil (MMF). The 
authors evaluated safety and looked for signals of efficacy. The results show improvement in 
modified Rodnan skin score (MRSS) during the treatment period with a numerically greater fall 
in those patients randomized to receive belimumab (MRSS -10 vs. -3), albeit statistically non-
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received belimumab, which clearly identified the clinical improvers compared to non-
responders. 
While the trends toward benefit for use of belimumab are promising for patients with 
SSc, this modern study design also highlights an important innovative paradigm shift in research 
approach of heterogeneous autoimmune connective tissue diseases. Specifically, in this study, 
the research design incorporated clinical data along with differential gene expression data, 
which allow for a deeper, more intelligent interpretation of the end-point results. Although the 
study was underpowered to show statistical significance for overall clinical outcomes, we are 
encouraged by the biological data that demonstrates expected drug target modulation along 
with identification of a subset of patients who derived substantial benefit. This is important 
since one can envision a truly translational research loop that not only allows bench data to 
drive clinical trials, but also clinical trial experiences to guide further biological research. 
Therefore, another approach towards discovery of our elusive Goldilocks Zone may be 
translating traditional clinical trials data into modern basic and clinical research that unravels 
the heterogeneity of SSc. Studies from Milano et al [10] and others [11] have shown, using 
novel techniques, that disease stratification and personalization is within reach. Going forward, 
biological precision will allow clinicians and researchers to reveal more powerful truths within 
small trials of uncommon and rare diseases. For instance, a very small study of Imatinib in 
active diffuse cutaneous systemic sclerosis used cytokine changes from skin biopsies and serum 
to determine if there were changes correlating with treatment response [12].  
SSc trial design should take into consideration various factors such as background 
immune suppression in all groups vs. not including ethics of GCP vs. gaining insight into how a 
treatment works, interpretation of pilot studies in general, use of genomics or other 
parameters to help to understand early trial results) and overall interpretation of 
pathophysiology of early SSc and role of B cell signalling. 
The strengths of the current study include randomization, blinding, a placebo control 
and the addition of study drug to a standardized background treatment (MMF). Limitations 
include the small patient number, single center design with potential bias, or center effect, and 
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This co-therapy makes it impossible to attribute any treatment effect solely to belimumab and 
may have blunted the difference in treatment response between the two groups. However, it 
allowed for all patients to receive standard of care which enhances recruitment and allows for 
good clinical practice. Future studies may need to determine if MMF is needed and also if other 
immune suppressive drugs could be used. This study provides data for a power calculation of a 
larger trial.  
The gene expression analysis may be difficult to interpret due to small numbers and 
there may be the MMF response and natural history confounding the belimumab effect. 
However, they showed modulation of B cell receptor activation and pro-fibrotic signaling in the 
belimumab arm and not in clinical improvers in the placebo group.  
In conclusion, novel early-stage trial designs that incorporate standard of care treatment 
and biomarkers to understand response such as gene expression within a randomized trial may 
be considered a template for future SSc trials.  
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